# Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.

> **NCT05216588** · — · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 149 (actual)

## Conditions studied

- COVID-19
- Immunocompromised Host

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05216588
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-26
- **Primary completion:** 2023-11-03
- **Final completion:** 2024-10-31
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05216588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05216588, "Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05216588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*